Tumor cell products typically stimulate osteoclast formation by upregulating RANKL or downregulating OPG (Osteoprotegerin) expression, thus shifting the RANKL/OPG ratio in favor of osteoclast-mediated bone resorption [24]. The gene discussed is TNFRSF11B; the disease is neoplasm.